Biologic Drug Analytics

Product and Process Development

hero-animation

Read Our New White Paper

Content and Degradation of Polysorbates in Biopharmaceutical Formulations

We present orthogonal analytical procedures for quantification of the total polysorbate content, determination of polysorbate identity, as well as characterization and quantification of polysorbate degradation products. The methods presented here provide a powerful toolbox for the control of polysorbate quality and stability in polysorbate-formulated biopharmaceutical drug products as requested by health authorities.

Biologics Product and Process Development

ProtaGene’s service portfolio includes a comprehensive suite of analytical methods to address the development of complex biologic drug substances, including full characterization panels, GMP level QC lot release, and stability methods.

Our global sites are equipped with modern, state-of-the-art equipment run under best-in-class quality systems for the analytical characterization of biopharmaceuticals, including structure, purity, chemical modification, aggregation, particle formation, and thermal stability. We offer analytical support service modules from research to market, such as:

  • bullet Created with Sketch.

    Developability and lead selection

  • bullet Created with Sketch.

    Preformulation/formulation development

  • bullet Created with Sketch.

    Real-time and accelerated stability

  • bullet Created with Sketch.

    Forced degradation program design and management

  • bullet Created with Sketch.

    Scale-up and process comparability

  • bullet Created with Sketch.

    Early MAM development and qualification

  • bullet Created with Sketch.

    Impurities and residuals process clearance studies

  • bullet Created with Sketch.

    Host Cell Protein Analysis

Analytical Solutions from Research to Market

Group Created with Sketch.
Research
Preclinical
Group 2 Created with Sketch.

Discovery – Pre-clinical

Biologic Candidate Evaluation, Optimization and Selection into IND

Group 3 Created with Sketch.
Phase I
Phase II
Phase III
Group 4 Created with Sketch.

Phase I – Phase III

Release, Clinical Data and Characterization Packages for Accelerating Phase I-III Programs through BLA

Group Created with Sketch.
Registration
Market
Group 2 Created with Sketch.

Registration – Market

Commercial-Stage Comparability Testing by Qualified Advanced Methods

Biologic Therapeutics Platform Expertise

Our deep experience advancing a diverse range of therapeutic platforms from research through market help the ProtaGene team design highly effective analytical programs that de-risk development and accelerate timelines to your next key milestones. Key biologic development areas include:

  • bullet Created with Sketch.

    Recombinant proteins—including complex, highly glycosylated proteins

  • bullet Created with Sketch.

    Multi-subunit complexes—protein, nucleotide, ligand

  • bullet Created with Sketch.

    mAbs

  • bullet Created with Sketch.

    ADCs and protein conjugates

  • bullet Created with Sketch.

    PEGylated proteins

  • bullet Created with Sketch.

    Bispecifics/multispecifics

  • bullet Created with Sketch.

    Fusion proteins

  • bullet Created with Sketch.

    Enzyme replacement therapies

  • bullet Created with Sketch.

    Biosimilars

  • bullet Created with Sketch.

    Vaccines, including subunit/recombinant

hero-animation

Analytical Systems

Enabled by state-of-the-art technology, ProtaGene offers an extensive range of analytical capabilities to support your biotherapeutic or gene & cell therapy projects.

hero-animation

Subscribe to Our Email List

Talk to Our Experts

Discover how ProtaGene can support your development programs

Contact Us